author-photo

Erica N Boswell

Harvard University

19

Papers

146

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

2015 Leukemia
Show All
- Source
- Cite
- Save
Citations (26)
Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm

2015 Oncologist
Show All
- Source
- Cite
- Save
Citations (38)
Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

2014 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients

2013 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

2013 Blood
Show All
- Source
- Cite
- Save
Citations (10)